CRK and neoplasm: Our results show that miR‐194 targets key molecules involved in tumor progression including HIF1A, MDM2,PIK3R2, MAPK1, IGF1R,BCL2, ITGB1, and CRK. Also, pathway analysis showed that miR‐194 targets critical pathways including the HIF‐hypoxia pathway, VEGF, mTOR, Wnt, TGF‐beta, and MAPK signaling pathways (Table S2).